Zymeworks, a Vancouver-based clinical-stage biopharmaceutical company, has made significant progress in the development and commercialization of biotherapeutics for cancer treatment. The company's attention is primarily focused on Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is currently at various clinical trial stages (Phase 1, Phase 2, and Phase 3) for the treatment of gastroesophageal adenocarcinomas, biliary tract, breast, colorectal, and endometrial cancers. Among its other primary product candidates is zanidatamab zovodotin, a HER2-targeted antibody-drug conjugate, with its Phase 1 clinical trial recently initiated for treating HER2-expressing tumors advanced or metastatic cancers. Alongside its oncology products, the company has a pipeline of preclinical product candidates and discovery-stage programs, including immuno-oncology agents and other therapeutic areas. Zymeworks has established strategic collaborations and partnerships with numerous corporations, notably BeiGene, Daiichi Sankyo, GlaxoSmithKline Intellectual Property Development Limited, Janssen Biotech, LEO Pharma A/S, Merck Sharp & Dohme Research GmbH, Celgene Corporation, Celgene Alpine Investment Co. LLC, Atreca, Inc., and Iconic Therapeutics, Inc. The company's incorporation was in 2003.
Zymeworks's ticker is ZYME
The company's shares trade on the NYSE stock exchange
They are based in Vancouver, British Columbia
There are 201-500 employees working at Zymeworks
It is zymeworks.com
Zymeworks is in the Healthcare sector
Zymeworks is in the Biotechnology industry
The following five companies are Zymeworks's industry peers: